BioMérieux Releases 2023 Universal Registration Document and Annual Financial Report

On March 28th, 2024, bioMérieux, a leading company in the diagnostics field, announced the filing of its 2023 Universal Registration Document, which includes the Annual Financial Report. This significant document was submitted to the French Autorité des Marchés Financiers (AMF) on March 27th, 2024. The submission marks a critical step in maintaining transparency and accountability to the company's stakeholders.

The Universal Registration Document provides a comprehensive overview of bioMérieux's financial performance throughout the year 2023, along with detailed insights into its operations, strategic direction, and future outlook. Stakeholders looking to access this document can find both French and English versions available on the bioMérieux website under the "Investors" section. This aims to facilitate a broader understanding and accessibility for international and local investors alike.

For further inquiries, bioMérieux has provided contact details for its Investor Relations, headed by Aymeric Fichet. Interested parties are encouraged to reach out via phone or email for more detailed information regarding the company's financial health and strategic initiatives.